A Phase 1 Study of TPI 287 Concurrent With Fractionated Stereotactic Radiotherapy (FSRT) in Treatment of Brain Metastases From Advanced Breast and Non-Small Cell Lung (NSCL) Cancer

The main purpose of this study is to see whether addition of TPI 287 to FSRT is safe and tolerable. Researchers also want to find out if adding TPI 287 to FSRT can help with better controlling the growth of brain lesions in people with brain metastases from their cancer.

开始日期2014-10-09

申办/合作机构

H. Lee Moffitt Cancer Center & Research Institute, Inc.

[+1]

NCT02133846

/ Completed临床1期IIT

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Sequential Cohort, Dose-Ranging Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of TPI 287 in Patients With Primary Four Repeat Tauopathies: Corticobasal Syndrome or Progressive Supranuclear Palsy

The purpose of this study is to determine the safety and tolerability [maximum tolerated dose (MTD) within planned dosing range] of intravenous (IV) infusions of TPI 287 administered once every 3 weeks for 9 weeks (for a total of 4 infusions) in patients with primary four repeat tauopathies (4RT), corticobasal syndrome (CBS; also called corticobasal degeneration, CBD) or progressive supranuclear palsy (PSP).

开始日期2014-05-01

申办/合作机构

The University of California, San Francisco

[+2]

NCT02047214

/ Terminated临床2期

Phase 2 Dose-Escalation Study of TPI 287 in Combination With Bevacizumab in Adults With Recurrent or Progressive Glioblastoma Following a Bevacizumab-Containing Regimen

The purpose of this study is to evaluate the safety, maximum tolerated dose (MTD), and efficacy of TPI 287 in combination with Avastin (bevacizumab) in subjects who have glioblastoma multiforme (GBM) that has progressed following prior radiation and temozolomide (TMZ) therapy and that has progressed following prior bevacizumab therapy.

开始日期2014-01-01

申办/合作机构

Cortice Biosciences, Inc.

100 项与 ARC-100 相关的临床结果

登录后查看更多信息

100 项与 ARC-100 相关的转化医学

登录后查看更多信息

100 项与 ARC-100 相关的专利（医药）

登录后查看更多信息

项与 ARC-100 相关的文献（医药）

2024-01-01·Neuro-oncology advances

Phase 1 trial of TPI 287, a microtubule stabilizing agent, in combination with bevacizumab in adults with recurrent glioblastoma

Article

作者: Benkers, Tara ; Singer, Samuel ; Duic, Paul J ; Hsu, Sigmund ; Rao, Mayank ; Goldlust, Samuel A ; Nabors, Louis B ; Silberman, Sandra L ; Mohile, Nimish ; Cappello, Lori ; Farmer, George

Abstract:

Background:

Recurrent glioblastoma (rGBM) has limited treatment options. This phase 1 protocol was designed to study the safety and preliminary efficacy of TPI 287, a central nervous system penetrant microtubule stabilizer, in combination with bevacizumab (BEV) for the treatment of rGBM.

Methods:

GBM patients with up to 2 prior relapses without prior exposure to anti-angiogenic therapy were eligible. A standard 3 + 3 design was utilized to determine the maximum tolerated dose (MTD) of TPI 287. Cohorts received TPI 287 at 140–220 mg/m2 every 3 weeks and BEV 10 mg/kg every 2 weeks during 6-week cycles. An MRI was performed after each cycle, and treatment continued until progression as determined via response assessment in neuro-oncology criteria.

Results:

Twenty-four patients were enrolled at 6 centers. Treatment was generally well tolerated. Fatigue, myelosuppression, and peripheral neuropathy were the most common treatment emergent adverse events. Dose-limiting toxicity was not observed, thus the MTD was not determined. Twenty-three patients were evaluable for median and 6-month progression-free survival, which were 5.5 months (mo) and 40%, respectively. Median and 12-month overall survival were 13.4 mo and 64%, respectively. The optimal phase 2 dose was determined to be 200 mg/m2.

Conclusions:

TPI 287 can be safely combined with BEV for the treatment of rGBM and preliminary efficacy supports further investigation of this combination.

2020-02-01·JAMA neurology1区 · 医学

Reactions to Multiple Ascending Doses of the Microtubule Stabilizer TPI-287 in Patients With Alzheimer Disease, Progressive Supranuclear Palsy, and Corticobasal Syndrome

1区 · 医学

Article

作者: Geldmacher, David S. ; Koestler, Mary ; Powers, Ryan ; Hare, Emma ; Shamloo, Merhdad ; Jung, Joo In ; Rosen, Howard J. ; Tsai, Richard M. ; Chuu, Emmeline L. ; Luong, Phi N. ; Mumford, Paige ; Rabinovici, Gil D. ; Wolf, Amy ; Miller, Zachary ; Boxer, Adam L. ; Ljubenkov, Peter A. ; Natelson-Love, Marissa ; Miller, Bruce L. ; Fagan, Anne M. ; Cobigo, Yann ; Wang, Ping ; Rojas, Julio C. ; McKinley, Emily C. ; Roberson, Erik D. ; Brown, Jesse A.

Importance:

Basket-design clinical trials that allow investigation of treatment effects on different clinical syndromes that share the same molecular pathophysiology have not previously been attempted in neurodegenerative disease.

Objective:

To assess the safety, tolerability, and pharmacodynamics of the microtubule stabilizer TPI-287 (abeotaxane) in Alzheimer disease (AD) or the 4-repeat tauopathies (4RT) progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS).

Design, Setting, and Participants:

Two parallel-design, double-blind, placebo-controlled phase 1 randomized clinical trials in AD and 4RT were conducted from December 20, 2013, through May 4, 2017, at the University of California, San Francisco, and University of Alabama at Birmingham. A total of 94 patients with clinically diagnosed AD (n = 39) and 4RT (n = 55) were screened; of these, 3 refused to participate, and 10 with AD and 11 with 4RT did not meet inclusion criteria. A total of 29 patients with AD, 14 with PSP, and 30 with β-amyloid-negative CBS (determined on positron emission tomography findings) were enrolled. Data were analyzed from December 20, 2013, through May 4, 2017, based on modified intention to treat.

Interventions:

Randomization was 8:3 drug to placebo in 3 sequential dose cohorts receiving 2.0, 6.3, or 20.0 mg/m2 of intravenous TPI-287 once every 3 weeks for 9 weeks, with an optional 6-week open-label extension.

Main Outcomes and Measures:

Primary end points were safety and tolerability (maximal tolerated dose) of TPI-287. Secondary and exploratory end points included TPI-287 levels in cerebrospinal fluid (CSF) and changes on biomarker, clinical, and neuropsychology measures.

Results:

A total of 68 participants (38 men [56%]; median age, 65 [range, 50-85] years) were included in the modified intention-to-treat analysis, of whom 26 had AD (14 women [54%]; median age, 63 [range, 50-76] years), and 42 had 4RT (16 women [38%]; median age, 69 [range, 54-83] years). Three severe anaphylactoid reactions occurred in TPI-287-treated patients with AD, whereas none were seen in patients with 4RT, leading to a maximal tolerated dose of 6.3 mg/m2 for AD and 20.0 mg/m2 for 4RT. More falls (3 in the placebo group vs 11 in the TPI-287 group) and a dose-related worsening of dementia symptoms (mean [SD] in the CDR plus NACC FTLD-SB [Clinical Dementia Rating scale sum of boxes with frontotemporal dementia measures], 0.5 [1.8] in the placebo group vs 0.7 [1.6] in the TPI-287 group; median difference, 1.5 [95% CI, 0-2.5]; P = .03) were seen in patients with 4RT. Despite undetectable TPI-287 levels in CSF, CSF biomarkers demonstrated decreased chitinase-3-like protein-1 (YKL-40) levels in the 4RT treatment arm (mean [SD], -8.4 [26.0] ng/mL) compared with placebo (mean [SD], 10.4 [42.3] ng/mL; median difference, -14.6 [95% CI, -30.0 to 0.2] ng/mL; P = .048, Mann-Whitney test).

Conclusions and Relevance:

In this randomized clinical trial, TPI-287 was less tolerated in patients with AD than in those with 4RT owing to the presence of anaphylactoid reactions. The ability to reveal different tau therapeutic effects in various tauopathy syndromes suggests that basket trials are a valuable approach to tau therapeutic early clinical development.

Trial Registration:

ClinicalTrials.gov identifiers: NCT019666666 and NCT02133846.

2016-12-01·Melanoma research4区 · 医学

A phase I study of TPI 287 in combination with temozolomide for patients with metastatic melanoma

4区 · 医学

Article

作者: Lecagoonporn, Srisuda ; Bedikian, Agop Y. ; Patel, Sapna P. ; Hwu, Wen-Jen ; Hwu, Patrick ; McQuade, Jennifer L. ; Posada, Liberty P. ; Amaria, Rodabe N. ; Davies, Michael A. ; Cain, Suzanne ; Bassett, Roland L.

TPI 287 is a synthetic taxane derivative with structural modifications allowing for central nervous system penetration and potential circumvention of multidrug resistance efflux pump mechanisms. The aim of this phase I study was to determine the maximum tolerated dose of the combination of TPI 287 and temozolomide in metastatic melanoma. Patients with stage IV unresectable or recurrent stage III melanoma were eligible. Stable untreated or treated brain metastases were allowed. Patients with previous taxane exposure were excluded. TPI 287 was administered intravenously on days 1, 8, and 15 and temozolomide was taken orally daily on days 1–5 of a 28-day cycle. Responses were assessed every two cycles according to WHO criteria. A total of 21 patients were enrolled. The maximum tolerated dose of the combination at this schedule was determined to be 125 mg/m2 intravenous of TPI 287 and 110 mg/m2 of oral temozolomide. The dose-limiting toxicity was neuropathy and six patients experienced grade III neuropathy. All patients were evaluable for tumor response. There were no complete responses; there were two partial responses and seven patients had stable disease (overall response rate 9.5% and disease control rate 42.9%). Three patients had stable disease in the brain despite progressive extracranial disease. The combination of TPI 287 and temozolomide is well tolerated in patients with metastatic melanoma, with the exception of neuropathy. The central nervous system penetration of both agents makes this a rational combination for further testing in primary and metastatic brain lesions.

项与 ARC-100 相关的新闻（医药）

2026-03-11

·FierceBiotech

CNS Pharma wipes glioblastoma pipeline clean in strategic pivot to fresh neurology, oncology targets

CNS Pharmaceuticals\' new approach is to bring in preclinical or clinical candidates with “defined value inflection points.”\n With a fresh leadership team settling in, CNS Pharmaceuticals is wiping its pipeline clean as it hunts for a new lead asset.After tapping a consulting firm for advice, the Houston-based biotech has elected to offload its glioblastoma candidates berubicin and TPI 287, the company announced in a March 11 release. CNS is now looking for partners that can take these assets off its hands while the company shops for promising new prospects in neurology and oncology.A phase 2 trial of berubicin in recurrent glioblastoma multiforme will continue through its expected completion in July, a spokesperson for CNS told Fierce Biotech this morning. The company had previously reported that berubicin failed to top fellow chemotherapy lomustine in this trial, though the study wasn’t powered to test for noninferiority.TPI 287, meanwhile, has not yet commenced its next phase of clinical development, according to the spokesperson, who explained that CNS won’t advance the asset any further. The biotech had previously said it planned to launch a phase 2 trial for the molecule, a derivative of the chemotherapy taxane.TPI 287 and berubicin are CNS\' only two assets, the spokesperson confirmed.The strategic pivot doesn’t come with any layoffs, the spokesperson added, and, instead, the new leadership team has “the intent to build and grow the company.”The Texas outfit’s new approach will be to bring in preclinical or clinical candidates with “defined value inflection points” that meet significant unmet medical needs in neurology or oncology, according to the release. “Strategic transformations are a common and often successful approach in biotechnology,” Rami Levin, who took over as CEO of CNS in January, said in the release. “With the right leadership experience and a disciplined, data-driven strategy, companies can transform their pipelines and create substantial value.”Not long after taking the helm, Levin brought on board a new chief financial officer, a chief technology officer, a chief business officer and a chief medical officer. He also wrote a letter to shareholders announcing that he was thoroughly evaluating the company’s pipeline and operations.In its most recent financial disclosure last November, CNS revealed cash reserves of about $9.9 million, which the biotech envisioned funding operations into the second half of this year.

临床2期高管变更财报

2026-03-11

·BioSpace

CNS Pharmaceuticals Launches New Corporate Strategy Focused on Building a High-Value Neurology and Oncology Pipeline

Newly formed executive team initiates global search for differentiated therapeutic assets for neurology and oncology indications, two of biopharma's largest and fastest-growing markets Strategic transformation driven by a comprehensive data analysis will enable new executive team to leverage decades of experience in these therapeutic areas Company pivoting from a singular focus on glioblastoma and will explore out-licensing of legacy assets berubicin and TPI 287 HOUSTON, TX / ACCESS Newswire / March 11, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) (the "Company"), a biotechnology company focused on building a pipeline of innovative therapies in high-value neurology and oncology markets, today announced that it has launched a new corporate growth strategy designed to build a high-value pipeline in neurology and oncology. The strategy is being led by the newly formed executive team with deep experience across neurology, oncology and rare disease drug development. The team is driving a disciplined, data-driven approach to identify, acquire and advance differentiated therapeutic programs capable of delivering meaningful clinical and commercial value. CNS Pharmaceuticals conducted an independent, rigorous evaluation of its existing pipeline, development priorities and broader market opportunities as part of a comprehensive strategic review. The process incorporated clinical probability-of-success modeling, competitive landscape assessments, regulatory pathway evaluations and risk-adjusted return analyses. The review was carried out in collaboration with external strategic advisors to ensure a disciplined, scientifically grounded and commercially focused path forward. Rami Levin, President and Chief Executive Officer of CNS Pharmaceuticals, commented, "We have made impactful progress in a very short period of time and are expecting 2026 to be a year of transformation and execution for CNS Pharmaceuticals. In parallel to a hand-picked, newly formed executive team, we immediately engaged a preeminent consulting firm and have now completed a robust and highly analytical review of our pipeline, development priorities and long-term positioning. We believe CNS Pharmaceuticals is uniquely positioned to leverage the deep expertise of our leadership team and a disciplined approach to capital allocation to build a next-generation biotechnology company focused on high-value opportunities in neurology and oncology." Based on the outcome of this review, the Company is moving towards a defined strategic focus on acquiring or in-licensing preclinical and clinical-stage assets in the therapeutic areas of neurology and oncology. CNS Pharmaceuticals intends to prioritize programs with strong biological rationale, differentiated mechanisms of action, clearly defined development and regulatory pathways and compelling clinical and commercial potential. Particular emphasis will be placed on assets with defined value inflection points and those addressing areas of significant unmet medical need, positioning the Company's pipeline for long-term growth and value creation. Neurology and oncology remain two of the most active and rapidly advancing sectors in biotechnology, supported by large and growing global markets, significant scientific innovation and well-established regulatory frameworks that can accelerate development timelines. Mr. Levin added, "Strategic transformations are a common and often successful approach in biotechnology. With the right leadership experience and a disciplined, data-driven strategy, companies can transform their pipelines and create substantial value. We believe CNS Pharmaceuticals is now prepared to follow this model as we identify, secure and advance differentiated neurology and oncology assets." As part of the strategic review, CNS Pharmaceuticals also evaluated its legacy programs. While scientifically valuable, TPI 287 and berubicin do not align with the Company's forward-looking growth strategy. CNS Pharmaceuticals plans to prepare comprehensive partnering packages to explore potential out-licensing of these assets, enabling the Company to concentrate its resources on advancing a new acquisition-driven pipeline. About CNS Pharmaceuticals, Inc. CNS Pharmaceuticals is a biotechnology company focused on developing innovative therapies for serious diseases in neurology and oncology. With an experienced executive team and a focus on high-value therapeutic opportunities, the Company is working to build a differentiated portfolio of assets addressing significant unmet medical needs. CNS Pharmaceuticals is committed to advancing novel treatments that have the potential to improve patient outcomes while creating long-term value for patients and shareholders. For more information, please visit , and connect with the Company on X and LinkedIn . Forward-Looking Statements Some of the statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this release include, without limitation, statements regarding the Company's pipeline prioritization and strategic development, the anticipated contributions of the new management team to the Company's growth, expectations regarding clinical development and regulatory strategy, and the Company's plans to explore out-licensing or strategic sales of legacy assets. These statements relate to future events, future expectations, plans and prospects. Although CNS Pharmaceuticals believes the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. CNS Pharmaceuticals has attempted to identify forward-looking statements by terminology including ''believes,'' ''estimates,'' ''anticipates,'' ''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,'' ''might,'' ''will,'' ''should,'' ''approximately'' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including market and other conditions and those discussed under Item 1A. "Risk Factors" in CNS Pharmaceuticals' most recently filed Form 10-K filed with the Securities and Exchange Commission ("SEC") and updated from time to time in its Form 10-Q filings and in its other public filings with the SEC. Any forward-looking statements contained in this press release speak only as of its date. CNS Pharmaceuticals undertakes no obligation to update any forward-looking statements contained in this press release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events, except as required by law. CONTACTS: Investor Relations Contact JTC Team, LLC Jenene Thomas 908.824.0775 CNSP@jtcir.com Business Development Contact CNS Pharmaceuticals, Inc. Dylan Wenke, Chief Business Officer dwenke@cnspharma.com SOURCE: CNS Pharmaceuticals, Inc. View the original press release on ACCESS Newswire

并购

2026-01-28

·BioSpace

CNS Pharmaceuticals Issues Letter to Shareholders - January 27, 2026

Newly Appointed President & Chief Executive Officer, Rami Levin, Discusses Plans for a New Era at CNS Pharmaceuticals Strategic Focus, Pipeline Optimization and Formalizing Roadmap for Near and Long-Term Value Creation HOUSTON, TX / ACCESS Newswire / January 27, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today issued a Letter to Shareholders from its newly appointed President and Chief Executive Officer, Rami Levin. Dear Fellow Shareholders, I am honored to write to you for the first time in my role as President and Chief Executive Officer of CNS Pharmaceuticals. I have stepped into this role with deep respect for the science, the people, and the shareholders who have supported this Company to date. CNS Pharmaceuticals was founded with a vision to address life threatening diseases with a high unmet medical need, and our focus now is to pursue that mission with clarity, discipline, and a strong commitment to execution and value creation for our shareholders. Strategic Imperative: Evaluation with Purpose Since joining CNS Pharmaceuticals as President & CEO, I have commenced a comprehensive evaluation of the company. This includes a thorough review of our pipeline, development priorities, operational structure, and capital allocation strategy. This process is not about narrowing our ambitions. It is about sharpening them with strategic intent to ensure that our Company is positioned to pursue meaningful, high-value therapeutic opportunities where we believe we can deliver real patient impact and robust long-term shareholder returns. Our evaluation will be guided by three core principles: Patients First. Every program we advance must address a serious condition with clear unmet medical need grounded in strong scientific and commercial rationale, a credible path to meaningful clinical benefit, and a realistic opportunity to improve patient outcomes. Pipeline Enrichment and Optimization. Alongside evaluating opportunities to enhance the pipeline through prioritization and business development opportunities, we are equally focused on optimizing our TPI 287 program. This includes honing the development and regulatory strategies for TPI 287 to ensure they are positioned as efficiently and effectively as possible for clinical advancement and a successful outcome. Disciplined Value Creation. We recognize the responsibility we have to our shareholders. Capital efficiency, milestone-driven execution, and transparent communication will be central to how we operate and make decisions. TPI 287: Our Lead Asset and Core Value Driver At the center of our strategy is TPI 287, our current lead asset and most significant potential value driver. TPI 287 has demonstrated meaningful data and promise in difficult-to-treat CNS and neuro-oncology indications, and we believe its potential has not yet been fully realized. Our focus now is on formalizing a development and regulatory pathway designed to create shareholder value by maximizing the probability of success while minimizing unnecessary risk. This includes: Refining clinical development plans with clear decision points Aligning with regulatory authorities Prioritizing indications and trial designs that offer the most efficient path to value Applying a disciplined, data-driven approach to capital allocation Raising capital towards data and pipeline milestone achievements Our goal is to make smart progress that builds credibility, optionality, and shareholder confidence. Strengthening the Roadmap Our task is to sharpen execution by aligning our capital and human resources, initially around TPI 287. At the same time, we will continue to evaluate opportunities to broaden and strengthen the pipeline in high-value indications where CNS Pharmaceuticals can build a differentiated and durable position. The potential expansion of our pipeline will be deliberate and strategy led. New programs and assets will be evaluated and selected based on their alignment with the Company's long-term strategic direction and how we intend to build and position the Company. Looking Ahead I firmly believe that with focus and a disciplined strategy, we can unlock our full potential and create meaningful value for patients and shareholders alike. As we move forward, our priority is to transform how CNS Pharmaceuticals operates by sharpening our focus, strengthening execution and ensuring that every decision we make is aligned with creating long-term value for our shareholders. In the near term, you can expect clear, consistent communication as we outline our strategy and demonstrate progress. We are committed to growing CNS Pharmaceuticals into a company defined by transparency, momentum and opportunity, and we believe the actions we are taking today position us well for the next phase of value creation. Thank you for your continued support and confidence. I look forward to keeping you informed as we progress through this evaluation process and work together to build the next chapter of CNS Pharmaceuticals. Sincerely, Rami Levin President and Chief Executive Officer About CNS Pharmaceuticals, Inc. CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company's drug candidate TPI 287 is an abeotaxane, which stabilizes microtubules and inhibits cell division, causing apoptosis and cell death. The initial clinical efficacy data suggest TPI 287 has the potential to cross the blood-brain barrier and treat CNS tumors. TPI 287 also has been tested in over 350 patients in clinical trials as a monotherapy and in combination with bevacizumab for the treatment of a range of diseases or conditions, including recurrent glioblastoma, recurrent neuroblastoma and medulloblastoma, advanced malignancies, advanced unresectable pancreatic cancer, metastatic melanoma, and breast cancer metastatic to the brain. To date TPI 287 appears to have both an excellent safety pro high tolerability among patients. For more information, please visit , and connect with the Company on X and LinkedIn . Forward-Looking Statements Some of the statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this release include, without limitation, statements regarding the Company's strategic evaluation, pipeline optimization plans, development and regulatory strategies for TPI 287, capital allocation strategy, plans to raise capital, expectations regarding clinical development, regulatory alignment, and value creation for shareholders. These statements relate to future events, future expectations, plans and prospects. Although CNS believes the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. CNS has attempted to identify forward-looking statements by terminology including ''believes,'' ''estimates,'' ''anticipates,'' ''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,'' ''might,'' ''will,'' ''should,'' ''approximately'' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including market and other conditions and those discussed under Item 1A. "Risk Factors" in CNS's most recently filed Form 10-K filed with the Securities and Exchange Commission ("SEC") and updated from time to time in its Form 10-Q filings and in its other public filings with the SEC. Any forward-looking statements contained in this press release speak only as of its date. CNS undertakes no obligation to update any forward-looking statements contained in this press release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events, except as required by law. CONTACTS: Investor Relations Contact JTC Team, LLC Jenene Thomas 908.824.0775 CNSP@jtcir.com SOURCE: CNS Pharmaceuticals, Inc. View the original press release on ACCESS Newswire

高管变更

100 项与 ARC-100 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
转移性黑色素瘤	临床2期	美国	Cortice Biosciences, Inc.	2013-09-01
复发性神经母细胞瘤	临床2期	美国	Cortice Biosciences, Inc.	2011-12-01
髓母细胞瘤	临床2期	美国	Cortice Biosciences, Inc.	2011-12-01
乳腺癌	临床2期	美国	Cortice Biosciences, Inc.	2011-08-16
乳腺癌脑转移	临床2期	美国	Cortice Biosciences, Inc.	2011-08-16
多形性胶质母细胞瘤	临床2期	美国	Cortice Biosciences, Inc.	2010-04-01
复发性胶质母细胞瘤	临床2期	美国	Cortice Biosciences, Inc.	2010-04-01
不能切除性胰腺癌	临床2期	美国	Cortice Biosciences, Inc.	2007-10-01
不能切除性胰腺癌	临床2期	西班牙	Cortice Biosciences, Inc.	2007-10-01
转移性前列腺癌	临床2期	美国	Cortice Biosciences, Inc.	2007-01-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02133846 \| NCT01966666 (Pubmed \| JAMA Neurol) 人工标引	临床1期	阿尔茨海默症 \| 皮质基底节变性 \| 进行性核上性麻痹	68	TPI-287	餘餘範鏇觸鑰淵廠壓獵(齋夢壓簾願獵選鬱築獵) = 廠鏇夢廠遞廠網網遞廠選夢鏇窪夢壓蓋齋鹽醖 (觸夢淵製窪獵構構獵鬱 ) 更多	积极	2020-02-01
NCT02133846 \| NCT01966666 (Pubmed \| JAMA Neurol) 人工标引	临床1期	阿尔茨海默症 \| 皮质基底节变性 \| 进行性核上性麻痹	68	Placebo	餘餘範鏇觸鑰淵廠壓獵(齋夢壓簾願獵選鬱築獵) = 鬱蓋顧糧壓膚鑰觸齋鏇選夢鏇窪夢壓蓋齋鹽醖 (觸夢淵製窪獵構構獵鬱 ) 更多	积极	2020-02-01
NCT01582152 (CTgov)	临床1/2期	复发性胶质母细胞瘤	12	Bevacizumab+TPI (TPI 287 160 mg/m2 + Bevacizumab)	憲製鹹簾鹽糧製繭夢鬱(繭壓鹹淵鬱壓簾願願鹽) = 糧醖膚蓋網鏇餘顧餘廠鏇糧願鹹網範餘獵艱範 (範鏇窪鏇築鑰簾淵鹹餘, 衊繭鏇憲構醖積製鹹壓 ~ 艱鹹窪憲夢製鬱膚膚製) 更多	-	2019-06-05
NCT01582152 (CTgov)	临床1/2期	复发性胶质母细胞瘤	12	Bevacizumab+TPI (TPI 287 140 mg/m2 + Bevacizumab)	憲製鹹簾鹽糧製繭夢鬱(繭壓鹹淵鬱壓簾願願鹽) = 簾廠製網構膚艱廠構獵鏇糧願鹹網範餘獵艱範 (範鏇窪鏇築鑰簾淵鹹餘, 衊蓋廠鹹壓憲積鹽築夢 ~ 願糧襯積膚獵衊積製觸) 更多	-	2019-06-05
NCT01332630 (CTgov)	临床2期	乳腺癌脑转移 \| 乳腺癌	24	Dexamethasone+TPI 287+Ranitidine+Benadryl	鑰築鑰糧範蓋製壓壓繭 = 齋鏇廠遞餘淵選窪窪壓鹹鏇壓蓋構鑰觸醖壓網 (醖艱構鏇膚餘範獵選選, 蓋願繭繭淵艱淵築鹽顧 ~ 齋鑰築蓋繭鹽鑰蓋廠鹽) 更多	-	2018-07-10
CB-017 (SNO2017)	临床1/2期	复发性胶质母细胞瘤 unmethylated MGMT promoter	-	TPI 287	構鏇築糧遞鑰範獵鬱簾(襯顧蓋窪壓顧鹹憲醖艱) = 齋廠衊鹽糧選鏇獵衊窪艱艱艱網繭餘廠鹹膚鏇 (製遞襯構繭艱顧鹽鏇壓 ) 更多	积极	2017-11-06
NCT01933815 (ASCO 12017 \| ASCO 22017) 人工标引	临床1/2期	复发性胶质母细胞瘤	24	bevacizumab+TPI 287	鑰淵窪製選憲範艱遞遞(積淵蓋廠範憲醖觸獵襯) = 鏇鏇願蓋遞願壓艱積衊鹹獵憲鬱憲壓構壓積獵 (醖繭願選選淵網繭鏇構 ) 更多	积极	2017-06-05
NCT01067066 (Pubmed \| Melanoma Res) 人工标引	临床1期	转移性黑色素瘤	21	temozolomide+TPI 287	顧醖醖餘艱製網壓鹽範(衊顧鹹齋醖遞壓繭餘艱) = neuropathy and six patients experienced grade III neuropathy 艱窪膚範積夢鹽膚壓淵 (淵願鏇構艱餘醖糧遞範 ) 更多	积极	2016-12-01
SNO2016	临床1/2期	复发性胶质母细胞瘤	-	TPI 287	鹹淵鑰餘膚鹹繭壓獵鑰(觸顧顧蓋衊蓋衊築積積) = myelosuppression (n=3) was the only drug-related grade 3/4 adverse event 選鑰淵夢觸願鹹襯築繭 (遞鹹膚糧膚糧衊糧鹽鬱 )	积极	2016-11-07
NCT01113463 (CTgov)	临床2期	多形性胶质母细胞瘤 \| 复发性胶质母细胞瘤	17	TPI 287	淵窪鏇齋顧齋衊淵積夢 = 壓窪廠襯夢糧範餘鏇構齋顧壓鹹築選鑰醖選襯 (觸鑰遞顧顧網鬱遞憲遞, 鏇窪網艱範製廠簾齋鬱 ~ 衊齋醖鹹廠廠願鑰餘築) 更多	-	2016-10-31
NCT00867568 (CTgov)	临床1期	复发性髓母细胞瘤 \| 神经母细胞瘤 \| 髓母细胞瘤	18	TPI 287	衊蓋淵繭簾艱鏇觸選夢 = 膚鹹襯憲糧獵鏇壓簾網鏇齋夢選遞壓壓網窪膚 (廠鏇選壓衊糧製鹽憲壓, 膚範憲觸鹽艱齋鬱繭齋 ~ 襯醖糧構衊鑰顧鹽鏇構) 更多	-	2016-10-28
NCT01505608 (CTgov)	临床1/2期	复发性神经母细胞瘤 \| 神经母细胞瘤	14	Temozolomide+Irinotecan (Arm A- Temozolomide and Irinotecan)	鬱襯衊範壓膚膚窪獵壓 = 鹽築蓋淵遞觸壓遞襯構膚淵鏇構鑰鑰醖鹹廠淵 (衊窪獵簾獵繭衊憲膚顧, 齋鏇憲壓夢蓋範築齋製 ~ 艱築鏇衊鏇積顧遞獵願) 更多	-	2016-10-28
NCT01505608 (CTgov)	临床1/2期	复发性神经母细胞瘤 \| 神经母细胞瘤	14	Temozolomide+TPI 287+Irinotecan (Arm B- Temozolomide/Irinotecan + TPI 287)	醖獵選蓋艱窪夢繭憲製 = 顧積淵鏇鏇淵衊艱顧艱繭廠蓋範簾獵積遞淵製 (構膚遞淵淵鹽鏇遞遞顧, 艱鹹簾積糧繭簾範觸鏇 ~ 願構襯廠鑰積繭製廠醖)	-	2016-10-28